B of A Securities Downgrades Kymera Therapeutics to Neutral, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has downgraded Kymera Therapeutics (KYMR) from Buy to Neutral and reduced the price target from $45 to $30.
January 03, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kymera Therapeutics was downgraded by B of A Securities from Buy to Neutral, with a price target decrease from $45 to $30.
The downgrade by a prominent analyst and the significant reduction in price target are likely to negatively impact investor sentiment and could lead to a short-term decline in KYMR's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100